tm logo
ENTOS
Live/Pending
PUBLICATION/ISSUE REVIEW COMPLETE

on 02 Apr 2024

Last Applicant/ Owned by

10230 Jasper Avenue

Edmonton, Alberta

CA

T5J4P6

Serial Number

97590573 filed on 14th Sep 2022

Registration Number

N/A

Correspondent Address

Theodore R. Remaklus

WOOD, HERRON & EVANS, L.L.P.

600 VINE STREET

SUITE 2800

CINCINNATI, OH 45202

Filing Basis

1. intent to use current

2. filed as use application

Disclaimer

NO DATA

ENTOS

Medical devices for the qualitative detection and testing of DNA and RNA in human specimens for the detection of influenza viruses and nucleic acid detection The English translation of the word "Entos" in the mark is "within". Reagents for scientific purposes for use in nucleic acid isolation and purification; cell culture media for laboratory use for use in the biotechnological industry; diagnoRead More

Classification Information


Class [010]
Medical Instrument Products


Medical devices for the qualitative detection and testing of DNA and RNA in human specimens for the detection of influenza viruses and nucleic acid detection

Class [009]
Computer & Software Products & Electrical & Scientific Products


Nucleic acid sequencers for scientific purposes

Class [005]
Pharmaceutical Products


Pharmaceutical and medicinal preparations and substances, namely, human vaccines, therapeutic proteins and antibodies for the treatment of infectious diseases, namely, viral infections, bacterial infections, fungal infections, parasitic infections and prion diseases, infections of multiple organ systems, namely, the lung in the name of pneumonia, kidneys in the name of pyelonephritis, gastrointestinal track in the nature of gastritis, enteritis, colitis, systemic blood infections in the nature of sepsis/septic shock, skin infections in the nature of cellulitis, central nervous system in the nature of meningitis, encephalitis, walled off infections in the nature of abscesses, liver in the nature of hepatitis, head and neck infections in the nature of conjunctivitis, uveitis, sinusitis; chronic diseases, namely, chronic neurological and nervous system diseases and other mental illnesses, chronic respiratory, pulmonary and lung diseases, chronic inflammatory diseases, chronic cardiovascular diseases, chronic liver diseases, chronic kidney diseases, chronic bone diseases, chronic eye diseases, chronic oral diseases, chronic blood diseases, chronic spleen diseases, chronic pancreatic diseases, chronic thyroid diseases, chronic reproductive disease, chronic gastrointestinal diseases, chronic skin diseases, chronic muscle diseases, chronic bone diseases and cancers in the nature of hematological cancers and solid organ cancers; vaccines that are viral, bacterial, fungal for human use; vaccines that are viral, bacterial, fungal for veterinary use; therapeutic and preventative cancer vaccines for human use; therapeutic and preventative cancer vaccines for veterinary use; diagnostic preparations for medical purposes for detecting genetic predispositions; pharmaceutical preparations for the treatment of genetic disorders; pharmaceutical preparations for the diagnosis, treatment and prevention of a variety of diseases and disorders, namely, cancer, inflammatory diseases and disorders, namely, inflammatory bowel diseases and disorders, inflammatory connective tissue diseases and disorders, inflammatory pelvic diseases and disorders, inflammatory muscle diseases and disorders, asthma, coeliac disease, hepatitis which is viral, alcoholic, autoimmune, inflammatory bowel disease, namely, Crohn's and ulcerative colitis, fatty liver disease, diabetes, endometriosis, arthritis, obesity, autoimmune diseases and disorders, metabolic diseases and disorders, namely, metabolic enzyme deficiencies, diabetes, hypoglycemia, gout, osteoarthritis, muscular dystrophy, anemia, genetic diseases and disorders, infectious diseases, namely, blood infections, respiratory infections, topical infections, cardiovascular diseases and disorders, neurological diseases and disorders, namely, Alzheimer's, Huntington's Disease, cerebral palsy, brain injury, spinal cord injury and seizure disorders, hematological diseases and disorders, dermatological diseases and disorders, namely, dermatitis, skin pigmentation diseases, psoriasis, eczema, acne, shingles, hives, rosacea, ophthalmological diseases and disorders, gastrointestinal diseases and disorders, genitourinary diseases and disorders, namely, urological diseases and disorders, infertility, sexually transmitted diseases, acute renal failure, benign ptostatic hyperplasia, endometrial ablation, renal diseases and disorders, respiratory diseases and disorders, connective tissues diseases and disorders, and enzyme deficiency diseases and disorders, rare and orphan diseases, and rare genetic diseases and disorders, namely, rare neurological and nervous system diseases and other mental illnesses, rare respiratory, pulmonary and lung diseases, rare inflammatory diseases, rare cardiovascular diseases, rare liver diseases, rare kidney diseases, rare bone diseases, rare eye diseases, rare oral diseases, rare blood diseases, rare spleen diseases, rare pancreatic diseases, rare thyroid diseases, rare reproductive disease, rare gastrointestinal diseases, rare skin diseases, rare muscle diseases, rare bone diseases; cell culture media for cultivating human, animal, plant or microorganism cells for use in the biotechnological industry

Class [001]
Chemical Products


The English translation of the word "Entos" in the mark is "within".

Mark Details


Serial Number

No 97590573

Mark Type

No Service/Collective Mark

Attorney Docket Number

No TORYS-96-122

44D Filed

Yes

44D Current

No

44E filed

No

44E Current

No

66A Filed

No

66A Current

No

Current Basis

No

No Basis

No

Legal History


Show more

Status DateAction Taken
17th Apr 2024NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
28th Mar 2024ON HOLD - ELECTRONIC RECORD REVIEW REQUIRED
22nd Mar 2024APPROVED FOR PUB - PRINCIPAL REGISTER
12th Mar 2024EXAMINER'S AMENDMENT ENTERED
11th Mar 2024EXAMINERS AMENDMENT -WRITTEN
11th Mar 2024EXAMINERS AMENDMENT E-MAILED
11th Mar 2024NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
11th Mar 2024ASSIGNED TO LIE
08th Mar 2024DIVISIONAL PROCESSING COMPLETE
06th Mar 2024CASE ASSIGNED TO INTENT TO USE PARALEGAL